Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Sarcoma, Kaposi 1Leukemia, Myelomonocytic, Chronic 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Cytarabine 13fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 8Etoposide 7Busulfan 7Methotrexate 6Cyclophosphamide 6Azacitidine 6Vorinostat 5Idarubicin 5Filgrastim 5Decitabine 5Daunorubicin 5tipifarnib 4Topotecan 4Carboplatin 4Biopsy 4veliparib 3sargramostim 3laromustine 3entinostat 3Thioguanine 3Tacrolimus 3Sunitinib 3Lenalidomide 3Imatinib Mesylate 3Cyclosporine 3Antilymphocyte Serum 3romidepsin 2merphos 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Chronic × Liposomes × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡